UPDATE
: Monday, December 16, 2019
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
HOME
Pharma
When will NOAC reversal agents be available in Korea?
Kim Yun-mi
승인 2019.03.07 15:52
댓글 0
Comments
0
Please leave the first comment.
[News Focus] You can use millions of patients’ data for research
Celltrion secures 11 synthetic drugs to advance to US market
Dong-A, Meiji Seika to conduct P1 trial for Stelara biosimilar
Patient cries for stem cell therapy approval to stop heart necrosis
[News Focus] You can use millions of patients’ data for research
Celltrion secures 11 synthetic drugs to advance to US market
Dong-A, Meiji Seika to conduct P1 trial for Stelara biosimilar
Patient cries for stem cell therapy approval to stop heart necrosis
여백
Most viewed
1
ABL Bio unveils new bispecific antibody at US meet
2
Aprogen, 1st Korean biotech firm to win unicorn status
3
Sanofi, Hanmi to look for new partner to commercialize efpeglenatide
4
Curexo launches 1st locally developed spine surgery robot
5
Samsung execs get jail term for destroying evidence
6
Samsung Bioepis to start P3 trial for Ontruzant in China
7
Eli Lilly Korea launches migraine prevention drug
8
Korean physician 1st Asian to do 1,000 robotic myomectomy surgeries
9
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
10
SK Bioscience's chickenpox vaccine world's 2nd to get WHO’s PQ certification
여백
Opinion
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
[Column] Korea should do better in diabetes management
[Column] Digital healthcare for efficient distribution of medical resources
여백
Back to Top